Business Context and Reporting Period
This Form 8-K, dated August 13, 2013, is filed by MRI Interventions, Inc. (noting the request metadata references Clearpoint Neuro, Inc., but the filing text identifies MRI Interventions, Inc.). The report addresses a non-reliance on previously issued financial statements due to accounting errors regarding warrant derivative liabilities. The filing covers restatements for the year ended December 31, 2012, and the three months ended March 31, 2013.
Key Financial Metrics and Restatement Impact
The filing details significant adjustments to balance sheet and income statement items resulting from the reclassification of warrant proceeds from equity to derivative liabilities. The filing text does not provide current revenue, operating cash flow, or liquidity ratios beyond the balance sheet adjustments.
| Financial Item | Period | Previously Reported | Adjustment | As Restated |
|---|---|---|---|---|
| Total Liabilities | Dec 31, 2012 | $11,288,847 | +$2,128,302 | $13,417,149 |
| Total Liabilities | Mar 31, 2013 | $14,855,488 | +$39,328 | $14,894,816 |
| Derivative Liabilities | Dec 31, 2012 | $789 | +$2,128,302 | $2,129,091 |
| Derivative Liabilities | Mar 31, 2013 | $3,771,310 | +$39,328 | $3,810,638 |
| Net Loss | Year Ended Dec 31, 2012 | $(5,707,136) | $(170,582) | $(5,877,718) |
| Net Loss | Three Months Ended Mar 31, 2013 | $(950,003) | +$126,255 | $(823,748) |
| Net Loss Per Share | Year Ended Dec 31, 2012 | $(0.14) | $(0.01) | $(0.15) |
| Net Loss Per Share | Three Months Ended Mar 31, 2013 | $(0.02) | $0.00 | $(0.02) |
Material Changes Versus Prior Period
The material change is a restatement of historical financial data rather than a change in operational performance. The company previously recorded net proceeds from its July 2012 and January 2013 equity private placements entirely as equity. Management determined that anti-dilution ("down round") provisions and net cash settlement features required these warrants to be accounted for as derivative liabilities. Consequently, total liabilities increased significantly, and additional paid-in capital was reduced.
Guidance, Outlook, and Risks
Management Commentary: Management and the Audit Committee concluded that the previously issued Form 10-K for 2012 and Form 10-Q for Q1 2013 should no longer be relied upon. The company is preparing amended filings (Form 10-K/A and Form 10-Q/A) to correct these non-cash errors. The fair value of warrants was recalculated using the Monte Carlo simulation valuation method.
Risks and Contingencies: The primary risk identified is the accuracy of historical financial reporting. The errors involved the application of derivative liability accounting standards to warrants issued in 2012 and 2013. The company has discussed these matters with its independent registered public accounting firm, Cherry Bekaert LLP.
Investor Verification Checklist
- Verify the filing of the upcoming Form 10-K/A for the year ended December 31, 2012, and Form 10-Q/A for the quarter ended March 31, 2013.
- Confirm the impact of the restated derivative liabilities on the company's current debt covenants and liquidity position.
- Review the specific terms of the July 2012 and January 2013 warrant agreements to understand the "down round" and net cash settlement provisions.
- Monitor for any further disclosures regarding the valuation methodology (Monte Carlo simulation) used for the warrant liabilities.